Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 36.00 0.00 07:48:43
Bid Price Offer Price High Price Low Price Open Price
34.00 37.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -9.58 -8.10 82
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 36.00 GBX

C4x Discovery (C4XD) Latest News

More C4x Discovery News
C4x Discovery Investors    C4x Discovery Takeover Rumours

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
24/6/202119:27C4X Discovery Holdings plc2,568

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 15:46:5234.50156,75054,078.75O
2021-06-24 15:27:3635.90350125.65O
2021-06-24 13:53:2335.0014,3035,006.05O
2021-06-24 13:53:0435.0014,3035,006.05O
2021-06-24 13:48:0935.003,1621,106.70O
View all C4x Discovery trades in real-time

C4x Discovery (C4XD) Top Chat Posts

C4x Discovery Daily Update: C4x Discovery Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 36p.
C4x Discovery Holdings Plc has a 4 week average price of 36p and a 12 week average price of 36p.
The 1 year high share price is 52p while the 1 year low share price is currently 13.50p.
There are currently 226,426,627 shares in issue and the average daily traded volume is 385,485 shares. The market capitalisation of C4x Discovery Holdings Plc is £81,513,585.72.
alloa2003: New board appointment which to be fair is just what the doctor ordered:- "20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect. Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly. Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based. His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior. We welcome Simon to the Board and look forward to working closely with him." Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value."
alloa2003: The irony is that if the share price/market cap was double or treble what it is now, people would not see these deals as pie in the sky - which they arent - they would be more believable. At the moment we are in the area where people look at the potential income and market cap and think, like we do, something doesnt look right. The truth is the market has not woken up or cant see past the initial fund raising debacle which saw us crash a couple of years ago. These shares were over £1 at one point after the IND deal (although I appreicate a lot more shares have since been issued). This deal is potentially twice the size, with earlier upfront payments but a greater degree of risk. Yes, there are still risks but the market has not adjusted the risk/reward ratio in the share price. If more deals are announced, and the market doesnt react, the company would be a prime takeover target. Potentially huge income streams which could be monitized if products make it to market - a takeover could potentially fund itself. Interesting....
astorcourt: C4XD would make a nice takeover target at multiples of current share price, given the potential of these deals. Clive has stated he is not interested in selling but he does have a track record in this area.
alloa2003: Over the next few days C4XD should get some decent press coverage - management interviews seem popular with Clive - and I would hope to see an updated broker research note. The share price rise must have been held back today, to a certain extent, by stale bulls, stuck in since the 50s and 60s, now able to get a huge chunk of their investment back.
bamboozler: I agree that this share price isn't driven by pi traders and hot money. Have a look at the share register..... it doesn't look anything like a normal aim ownership structure and has seriously solid institutional support. It'll move driven by what they achieve in the clinic and with future partnerships and transactions rather than day trading momentum...... I'm fine with that.
alloa2003: Even clarifying the maximum income for the INDV deal would see the share price rocket. One or two more deals of that size would put us in a different league. The kicker with this company will be the cumulatve repetitive income from each individual molecule going forwards.
alloa2003: He has been making all of the right noises for years, just needs to deliver now. On balance I think he will deliver. However, his approach is not news driven which drives share prices. We will only hear about deals when they have been signed.
alloa2003: Are the directors taking us for fools? Where is the incentive to push the share price? The exercise price should have been 50p minimum. If all is good behind the scenes, as they keep telling us, then 50p should not be a problem. As a % of the share capital it is irrelevant but it is the principle of institutions and now directors taking advantage of the relatively depressed share price (compared to 12 months ago).
the stigologist: Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill Gates Interestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn Schrodinger is the nearest equivalent to C4XD IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+ The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap) Clive today told us the NRF2/IL17/a4B7 projects have similar potential
alloa2003: Nice update with a mention of work in the area of Covid-19:- 25 August 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update. Clive Dix, CEO of C4XD, commented: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the COVID-19 pandemic, in particular, the continued headway in our key inflammation programmes. Importantly, Indivior recently commenced a Phase 1 clinical trial with our selective Orexin-1 antagonist, C4X_3256, for the treatment of opioid dependence and we eagerly await those results in due course. Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease (IBD). This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease. "We are also pleased to announce a new partnership with the GEN-COVID Consortium in Italy. The collaboration will utilise Taxonomy3® to examine genetic data from a significant number of COVID-19 patients to identify genes specifically associated with severe COVID-19 disease. The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development." C4XD has continued to make progress across key programmes in its portfolio: · Indivior has commenced a Phase 1 clinical trial for C4XD's novel selective Orexin-1 antagonist, C4X_3256 (also known as INDV-2000), for the treatment of opioid dependence with the first patient now dosed (hxxps:// This single ascending dose study in healthy volunteers is anticipated to complete by year end. · One of C4XD's lead NRF-2 activator molecules C4X_6746, has recently been shown to significantly inhibit the disease score in a pre-clinical model of IBD in a dose-related manner. Candidate nomination studies continue. · The lead optimisation stage has been initiated for C4XD's novel oral IL-17 inhibitor programme for the treatment of Psoriasis with the aim of identifying further improved small molecules to drive towards a pre-clinical candidate shortlist. We note that Leo Pharma A/S has recently announced that it has identified the first oral IL-17 inhibitor IND-ready candidate with clinical studies expected to be initiated soon. This provides further confidence that the challenge of developing a small molecule alternative to injectable monoclonal antibodies to target IL-17 can be achieved and there has been increased interest from potential pharma partners. · Significant progress has been made on C4XD's early oral inhibitor programme targeting a4b7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD's Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of a4b7 integrin in vivo following oral dosing. · The LifeArc risk-share collaboration on an oral small molecule inhibitor programme for the treatment of haematological cancers and inflammatory disease continues to progress well despite being impacted by COVID-19. Three novel series have been identified by harnessing C4XD's Conformetrix technology and recent data has demonstrated functional cell activity and oral bioavailability for all three series. Optimisation continues with the aim of demonstrating functional inhibition of the target in vivo following oral dosing. · C4XD has recently entered a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy led by Professor Alessandra Renieri of the University of Siena. The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3® to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with COVID-19. Taxonomy3® will analyse genetic data from a significant number of COVID-19 positive patients collected by the consortium to identify genes associated with severe COVID-19 disease. The aim is to identify a unique genetic signature that can successfully predict mild vs. severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment.
C4x Discovery share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 07:10:44